Last updated: April 25, 2026
Who supplies the pharmaceutical ingredient (API) for fosphetyntoin sodium?
Fosphenytoin sodium is supplied through a mix of branded injectable manufacturers and generic/contract manufacturers that produce either the finished sterile product or the underlying active substance used in that product.
Because sourcing is product- and dossier-specific (sterile parenteral controls, DMF/ASMF linkage, and country approvals), the most reliable supplier set for business decisions is the set of approved finished-dose manufacturers and publicly documented manufacturing sites tied to regulatory filings.
Which firms supply approved fosphetyntoin sodium injectables?
The injectable product is marketed under multiple brand names and strengths (commonly 50 mg phenytoin equivalents per mL, typically as fosphetyntoin sodium in injection/infusion formats depending on region).
Supplier set (finished-dose manufacturers and marketing authorisation holders) commonly associated with fosphetyntoin sodium injectables across major regulated markets:
| Category |
Supplier / Brand owner (examples) |
Typical product form |
Notes for diligence |
| Originator/legacy branded |
Parke-Davis (Pfizer legacy) (where applicable by region) |
Injectable |
Historical origin; current regional MA holders vary. |
| Generic injectables |
Hospira (Pfizer legacy assets in many markets) |
Injectable |
Site and MA holder vary by geography. |
| Generic injectables |
Mylan (often via generic injectables footprint) |
Injectable |
Dossier mapping to sterile manufacturing needed by country. |
| Generic injectables |
Sandoz |
Injectable |
Verify strength, salt form, and sterile process site. |
| Generic injectables |
Teva |
Injectable |
Confirm packaging format and strength mapping. |
Operational sourcing point: For procurement, you generally buy either (a) the finished sterile injectable from an approved manufacturer, or (b) sterile fill-finish via a CDMO that has regulatory clearance for the specific dossier. Pure “API-only” procurement is less common for sterile injectables because the sterile product is what moves through hospital supply chains.
Which CDMO/sterile fill-finish models are used in fosphetyntoin sodium injection supply?
Fosphetyntoin sodium injectables are produced under sterile manufacturing regimes. In practice, suppliers fall into two archetypes:
-
Finished-dose manufacturers with sterile manufacturing sites
- Produce and release the injection directly.
- Provide end-to-end compliance for sterility assurance, aseptic processing, packaging integrity, and labeling.
-
Contract sterile fill-finish and packaging providers
- Perform fill-finish for a marketing authorisation holder.
- Operate under the approved quality system for the specific dossier and change control.
For supplier shortlists, diligence typically confirms:
- Aseptic processing method (terminal sterilization vs aseptic fill)
- Sterility assurance level (SAL) approach
- Particle control and endotoxin controls
- Extractables/leachables strategy for the primary container-closure system
- Batch release testing for potency and assay/related substances
What procurement-ready supplier information should be validated per region?
Even when the “company name” appears as a supplier, procurement requires a link to:
- Local marketing authorisation holder (MAH) or tendering entity
- GMP manufacturing site(s) for the specific product strength and packaging
- Regulatory dossier reference (DMF/ASMF linkage for API, or CEP/DMF references for finished dose)
- Shelf-life and storage for each stock-keeping unit (SKU)
- Lot release location and importation pathway
Below is the diligence checklist used to convert “supplier name” into an actionable procurement vendor:
| Validation item |
What to confirm |
Why it matters for fosphetyntoin sodium |
| Manufacturing site |
GMP site address for the exact SKU |
Sterile injectable supply depends on site clearance. |
| Strength and equivalency |
“phenytoin equivalents” per mL mapping |
Strength labeling varies by region and packaging. |
| Container closure |
Vial material and stopper system |
Compatibility and extractables risk drive stability. |
| Release specs |
Assay, impurities/related substances, endotoxin |
Potency and impurity control must match dossier specs. |
| Clinical batch history |
Batch size and comparable lots |
Impacts reliability for hospitals and procurement planning. |
Where does fosphetyntoin sodium supply concentration usually sit?
For sterile injectable anticonvulsants, supply concentrates among:
- Companies with established injectable sterile portfolios
- Firms with regulatory histories for parenterals in epilepsy/neurology and emergency hospital use
- Manufacturers with scale for low-volume but high-criticality ICU/emergency dosing
How to structure a supplier shortlist for R&D, procurement, or tendering
A practical shortlist uses two tiers:
Tier 1: Finished-dose suppliers
Use only manufacturers that can supply the approved sterile injectable in the target region.
Target outcome: confirmed ability to ship the exact SKU with documented GMP release.
Tier 2: API/dossier-linked sources (if applicable)
Only include API suppliers if they can prove the API is tied to the sterile dossier you will use, including:
- ASMF/DMF linkage
- Change notification history
- Compatibility data for conversion into the sterile injectable manufacturing process
Which supplier documents typically provide the fastest sourcing path?
Use documents that directly connect the supplier to the product quality system:
- EMA national/regional product information
- FDA Orange Book entries (U.S.)
- National product registers for MA holders
- CEPs where applicable
- GMP certificate details for the specific manufacturing site
Key Takeaways
- Fosphetyntoin sodium injectable supply is dominated by finished-dose sterile manufacturers rather than “API-only” sourcing for procurement and hospital tenders.
- Shortlisting should prioritize suppliers that can provide the exact approved SKU with mapped GMP sites and dossier-linked quality controls.
- For sterile parenterals, procurement risk centers on sterile fill-finish controls, container-closure compatibility, and dossier-linked release testing, not only on the company name.
FAQs
-
Is fosphetyntoin sodium usually procured as API or finished sterile injectable?
Finished sterile injectable is the dominant procurement pathway for healthcare systems and tendering because hospitals require released, sterile, labeled product.
-
What matters most in choosing a supplier for fosphetyntoin sodium injection?
The supplier must match the approved strength format, sterile manufacturing controls, and GMP manufacturing site tied to the dossier for the region.
-
Can the same supplier sell different strengths under the same brand?
Yes, but each strength/SKU can map to different manufacturing runs or labeling configurations, so validation must be SKU-specific.
-
Why do dossiers and DMF/ASMF linkage matter for API sourcing?
Sterile injectable quality depends on the API’s impurity profile and specifications being compatible with the approved finished-dose controls and release testing.
-
What is the fastest way to de-risk supply continuity for fosphetyntoin sodium?
Use at least two Tier 1 finished-dose suppliers in the target geography and validate lot release and storage specs per SKU.
References
[1] FDA. (n.d.). Drug Product and Labeling Data for fosphenytoin sodium (where available via Orange Book entries and related listings). U.S. Food and Drug Administration.
[2] European Medicines Agency (EMA). (n.d.). Product information and EPAR-related documents for fosphetyntoin/fosphenytoin-containing injectables (by national submissions). EMA.
[3] National regulatory product registers (varies by country). (n.d.). Marketing authorisation holder and manufacturing site information for fosphetyntoin sodium injection.
